Robert Uger, Chief Scientific Officer at Trillium Therapeutics Inc. (TRIL), sold 7,292 shares at $14.75 ($108K) on 2021-01-07, disclosed to the SEC on 2021-01-11.
Open-market sale of $108k TRIL by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.75 | 3,646 | $54K | 50.0% |
| 2 | $14.75 | 3,646 | $54K | 50.0% |
| Total | $14.75 avg | 7,292 | $108K | 100% |
| Filing → |
| TRIL | SELL | 2021-05-11 | $34K | — | Filing → |
| TRIL | SELL | 2021-04-09 | $39K | — | Filing → |
| TRIL | SELL | 2021-03-15 | $35K | — | Filing → |